[Role of PPARγ, a transcription factor in cardiovascular disease].

Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand activated transcription factor known to regulate fatty acid metabolism. Thiazolidinediones (TZDs), PPARγ synthetic agonists, currently used to treat patients with type 2 diabetes, have been shown to lower the blood pressure and protect against vascular diseases such as atherosclerosis. In line with these findings, it has been reported that individuals with loss-of-function mutations of PPARγ developed sever early-onset hypertension in addition to metabolic abnormalities. Accumulating evidences suggest PPARγ in the vasculature has protective effects on cardiovascular disease despite unclear mechanism. Because of ubiquitous expression of PPARγ, TZDs are well-known to be associated with serious side effects such as weight gain, fluid retention, and bone fractures. Thus identification of mechanisms on tissue-specific PPARγ activity may lead to the development of targeted treatment which is characterized by no deleterious effects. This review discusses role of PPARγ in cardiovascular disease.

• Publication year

  2019

• Venue

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1254/fpj.154.56PMID 31406043
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interference With Endothelial PPAR (Peroxisome Proliferator–Activated Receptor)-&ggr; Causes Accelerated Cerebral Vascular Dysfunction in Response to Endogenous Renin-Angiotensin System Activation

  2018cited by this paper
• Hypertension-Causing Mutation in Peroxisome Proliferator–Activated Receptor &ggr; Impairs Nuclear Export of Nuclear Factor-&kgr;B p65 in Vascular Smooth Muscle

  2017cited by this paper
• Endothelial PPAR-γ provides vascular protection from IL-1β-induced oxidative stress.

  2016cited by this paper
• Protective Role for Tissue Inhibitor of Metalloproteinase-4, a Novel Peroxisome Proliferator–Activated Receptor-&ggr; Target Gene, in Smooth Muscle in Deoxycorticosterone Acetate–Salt Hypertension

  2016cited by this paper
• Interference with PPARγ in endothelium accelerates angiotensin II-induced endothelial dysfunction.

  2016cited by this paper
• Flexible pulse-controlled fiber laser

  2015cited by this paper
• Interference With Peroxisome Proliferator-Activated Receptor-&ggr; in Vascular Smooth Muscle Causes Baroreflex Impairment and Autonomic Dysfunction

  2014cited by this paper
• Role of Peroxisome Proliferator–Activated Receptor-&ggr; in Vascular Muscle in the Cerebral Circulation

  2014cited by this paper
• Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?

  2013cited by this paper
• Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle.

  2013cited by this paper
• Peroxisome Proliferator-Activated Receptor-&ggr; Mutations Responsible for Lipodystrophy With Severe Hypertension Activate the Cellular Renin–Angiotensin System

  2013cited by this paper
• PPARγ: no SirT, no service.

  2013cited by this paper
• Loss of Perivascular Adipose Tissue on Peroxisome Proliferator–Activated Receptor-&ggr; Deletion in Smooth Muscle Cells Impairs Intravascular Thermoregulation and Enhances Atherosclerosis

  2012cited by this paper
• GQ-16, a Novel Peroxisome Proliferator-activated Receptor γ (PPARγ) Ligand, Promotes Insulin Sensitization without Weight Gain

  2012cited by this paper
• PPARγ is an E3 ligase that induces the degradation of NFκB/p65

  2012cited by this paper
• PPAR&ggr; Regulates Resistance Vessel Tone Through a Mechanism Involving RGS5-Mediated Control of Protein Kinase C and BKCa Channel Activity

  2012cited by this paper
• Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ.

  2012cited by this paper
• Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPARγ and RhoA/Rho-kinase.

  2012cited by this paper
• Disruption of Endothelial Peroxisome Proliferator-Activated Receptor &ggr; Accelerates Diet-Induced Atherogenesis in LDL Receptor-Null Mice

  2012cited by this paper
• A role for CNS PPARγ in the regulation of energy balance

  2011cited by this paper
• Obesity-linked phosphorylation of PPARγ by cdk5 is a direct target of the anti-diabetic PPARγ ligands

  2010cited by this paper
• Incidence and mortality of hip fractures in the United States.

  2009cited by this paper
• Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production.

  2009cited by this paper
• Obesity, inflammation, and atherosclerosis

  2009cited by this paper
• Integration of metabolism and inflammation by lipid-activated nuclear receptors

  2008cited by this paper
• Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension.

  2008cited by this paper
• Interference With PPARγ Signaling Causes Cerebral Vascular Dysfunction, Hypertrophy, and Remodeling

  2008cited by this paper
• Metabolic Syndrome, Inflammation, and Incident Heart Failure in the Elderly: The Cardiovascular Health Study

  2008cited by this paper
• Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)

  2007cited by this paper
• PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties.

  2007cited by this paper
• Effects of thiazolidinediones on blood pressure

  2007cited by this paper
• Macrophage-specific PPARγ controls alternative activation and improves insulin resistance

  2007cited by this paper
• Can PPARgamma agonists have a role in the management of obesity-related hypertension?

  2006cited by this paper
• Aspects of the regulatory mechanisms of PPAR functions: Analysis of a bidirectional response element and regulation by sumoylation

  2006cited by this paper
• Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance

  2006cited by this paper
• PPARgamma in endothelial cells influences high fat diet-induced hypertension.

  2005cited by this paper
• PPARgamma in the control of brown adipocyte differentiation.

  2005cited by this paper
• A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.

  2004cited by this paper
• Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma.

  2004cited by this paper
• Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelA

  2004cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study.

  2003cited by this paper
• Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA.

  2003cited by this paper
• Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.

  2003cited by this paper
• Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study

  2003cited by this paper
• Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells.

  2001cited by this paper
• Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.

  2000cited by this paper
• Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension

  1999cited by this paper
• Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion.

  1996cited by this paper
• Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

  1995cited by this paper

• The role of PPARγ in intermittent hypoxia-related human umbilical vein endothelial cell injury

  2022cites this paper
• Traumatic Brain Injury-Mediated Neuroinflammation and Neurological Deficits are Improved by 8-Methoxypsoralen Through Modulating PPARγ/NF-κB Pathway

  2022cites this paper
• Recent advancement on development of drug-induced macrophage polarization in control of human diseases.

  2021cites this paper
• WISP1 alleviates lipid deposition in macrophages via the PPARγ/CD36 pathway in the plaque formation of atherosclerosis

  2020cites this paper